Lrrk2 and Lewy body disease

作者：Owen A. Ross, Mathias Toft, Andrew J. Whittle, Joseph L. Johnson, Spiridon Papapetropoulos, Deborah C. Mash, Irene Litvan, Mark Forrest Gordon, Zbigniew K. Wszołek, Matthew James Farrer, Dennis W. Dickson · 发表于：Annals of Neurology · 年份：2006 · DOI：10.1002/ana.20731 · 被引用次数：270 · 研究领域：Parkinson's Disease Mechanisms and Treatments、Nuclear Receptors and Signaling、Neurological diseases and metabolism

OBJECTIVE: The Lrrk2 kinase domain G2019S substitution is the most common genetic basis of familial and sporadic parkinsonism. Patients harboring the G2019S substitution usually present with clinical Parkinson's disease. METHODS: Herein, we report that the most common neuropathology of G2019S-associated Parkinson's disease is Lewy body disease. RESULTS: Lrrk2 G2019S was observed in approximately 2% (n = 8) of our Parkinson's disease/Lewy body disease cases (n = 405). The mutation was also found in one control subject and one Alzheimer's disease patient, reflecting reduced penetrance. INTERPRETATION: Therapeutic strategies targeted at modulating Lrrk2 kinase activity may be important to treat patients with genetically defined familial or typical sporadic Parkinson's disease.